PCSK9 and coronary artery disorder: Therefore, we used these test kits to examine the utilization of LDL in CHD patients after injection of a Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor known to be implicated in cholesterol homeostasis (Figure 2).